Bruce Strober, MD, PhD
Director, Dermatology Clinical TrialsNYU Medical Center
Member of the Healthcare Council
Bruce Strober, MD, PhD, is an Associate Director of the Dermatology Clinical Trials Unit, Co-Director of Psoriasis and Psoriatic Arthritis Center, and Assistant Professor at New York University. Dr. Strober is an expert on biologic therapies for psoriasis and his specialty includes general medical dermatology with a particular interest in psoriasis. Dr. Strober has participated in many of the clinical trials addressing systemic and topical therapies for inflammatory skin disease. He has consulted for various companies including Amgen, Wyeth, Genentech, Abbott, Centocor, Astellas, Biogen-Idec, and Novartis. (This is me - Update Profile)
| 2007 - present | Director, Dermatology Clinical Trials NYU Medical Center |
|---|---|
| 2003 - present | Co-Director, Psoriasis, Psoriatic Arthritis Center NYU Medical Center |
| 2002 - present | Assistant Professor New York University (inc) |
GLG Study Groups with Bruce Strober, MD, PhD(?)
| Study Group Name | Members |
|---|---|
| Dermatologists (US) | 581 |
| Physicians who Treat Rosacea (US) | 125 |
| CellCept Prescribers | 51 |
| Physicians who treat Actinic keratoses | 88 |
GLG NewsSM Analyses by Bruce Strober, MD, PhD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Bruce Strober, MD, PhD has not published any public GLG News analyses.
View all GLG News in Healthcare
View all GLG News in Healthcare
GLG InstituteSM Seminars with Bruce Strober, MD, PhD(?)
Bruce Strober, MD, PhD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare
View all GLG InstituteSM Seminars in Healthcare
Request a project with Bruce Strober, MD, PhD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
40 of the leading 50
global mutual funds
global mutual funds
15 of the leading 20
global banks
global banks
8 of the leading 10
private equity firms
private equity firms
90%+ client subscription renewal rate

